- Home
- ZNTL vs FENC Comparison
ZNTL vs FENC Comparison
Compare ZNTL & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- FENC
- Stock Information
- Founded
- ZNTL 2014
- FENC 1996
- Country
- ZNTL United States
- FENC United States
- Employees
- ZNTL N/A
- FENC N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZNTL Health Care
- FENC Health Care
- Exchange
- ZNTL Nasdaq
- FENC Nasdaq
- Market Cap
- ZNTL 137.9M
- FENC 156.9M
- IPO Year
- ZNTL 2020
- FENC 2001
- Fundamental
- Price
- ZNTL $1.63
- FENC $6.09
- Analyst Decision
- ZNTL Buy
- FENC Strong Buy
- Analyst Count
- ZNTL 8
- FENC 2
- Target Price
- ZNTL $8.53
- FENC $14.00
- AVG Volume (30 Days)
- ZNTL 852.5K
- FENC 120.6K
- Earning Date
- ZNTL 03-26-2025
- FENC 03-10-2025
- Dividend Yield
- ZNTL N/A
- FENC N/A
- EPS Growth
- ZNTL N/A
- FENC N/A
- EPS
- ZNTL N/A
- FENC N/A
- Revenue
- ZNTL $67,425,000.00
- FENC $47,538,000.00
- Revenue This Year
- ZNTL N/A
- FENC $28.99
- Revenue Next Year
- ZNTL N/A
- FENC $63.21
- P/E Ratio
- ZNTL N/A
- FENC N/A
- Revenue Growth
- ZNTL N/A
- FENC 123.69
- 52 Week Low
- ZNTL $1.58
- FENC $3.96
- 52 Week High
- ZNTL $16.27
- FENC $11.29
- Technical
- Relative Strength Index (RSI)
- ZNTL 36.50
- FENC 39.43
- Support Level
- ZNTL $1.78
- FENC $6.25
- Resistance Level
- ZNTL $2.02
- FENC $6.90
- Average True Range (ATR)
- ZNTL 0.15
- FENC 0.34
- MACD
- ZNTL -0.00
- FENC -0.04
- Stochastic Oscillator
- ZNTL 3.53
- FENC 19.82
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.